UPDATE: Spartan Bioscience Gets FDA OK for Rapid CYP2C19 Assay | GenomeWeb

This article has been updated to clarify that the test has not been cleared for use in a point-of-care setting.

NEW YORK (GenomeWeb News) – Canadian molecular diagnostics developer Spartan Bioscience said today that the US Food and Drug Administration has granted 510(k) clearance to the Spartan RX CYP2C19 assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.